[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576696":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants treated with lisocabtagene maraleucel",null,[12],"Biological: Lisocabtagene maraleucel",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"BIOLOGICAL","Lisocabtagene maraleucel","According to US Prescribing Information",[9],[20],{"name":21,"affiliation":21,"role":22},"Bristol-Myers Squibb","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":30,"role":26,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Center for International Blood and Marrow Transplant Research (CIBMTR)","RECRUITING","Milwaukee","Wisconsin","53226","United States",{"type":40,"coordinates":41},"Point",[42,43],-87.90647,43.0389,{"lat":43,"lon":42},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100576696",false,"NCT06788652","A Study of Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed\u002FRefractory Mantle Cell Lymphoma in the Post-Marketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of liso-cel infusion.\n* Participants treated with non-conforming CAR T-cell product.","ALL","18 Years",{"count":56,"type":57},300,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).",[61],"Mantle Cell Lymphoma (MCL)",[61],"2025-02-21",{"date":65,"type":66},"2025-02-24","ACTUAL",{"date":68,"type":66},"2025-02-04",{"date":70,"type":57},"2044-09-30",{"name":5,"class":6},1]